FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps

What Was Tested

This registered not phased trial tested Desmopressin.

It had two arms (groups): Intervention (experimental) and Control (active comparator).

Participants will undergo Functional Endoscopic Sinus Surgery (FESS) without preoperative intranasal desmopressin.

The registry classes the interventions as drug and procedure.

More on the Plan

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory condition affecting the nose and paranasal sinuses.

Intraoperative bleeding is an important consideration during FESS because blood can interfere with visualization of the surgical field and make identification of anatomical structures and surgical dissection more difficult.

The study is designed to investigate whether preoperative intranasal desmopressin may influence operative conditions during FESS.

Eligible patients with chronic rhinosinusitis with bilateral nasal polyps who are scheduled for elective FESS will be considered for participation.

Who Took Part

174 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients aged 18-60 years. Diagnosed cases of chronic rhinosinusitis with bilateral nasal polyps. Patients planned for elective Functional Endoscopic Sinus Surgery (FESS). Patients with ASA physical status I or II.

The full record lists 4 inclusion and 6 exclusion criteria; among the exclusions: known bleeding disorders; fungal rhinosinusitis with polyps; use of anticoagulant or antiplatelet drugs.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

The participants were allocated by chance, so the Desmopressin group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Desmopressin study: the participants and staff both knew the treatment.

It started in 2026-10-15 with completion listed for 2027-10-14.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery (time frame: During surgery (intraoperative period)).

It also tracked 1 secondary outcome, for example Quality of Surgical Field During FESS.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Desmopressin in 174 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Desmopressin compound page, all human trials.